Last reviewed · How we verify
Combined with voriconazole
This drug works by inhibiting the activity of a specific enzyme.
This drug works by inhibiting the activity of a specific enzyme. Used for Treatment of invasive aspergillosis when used in combination with voriconazole.
At a glance
| Generic name | Combined with voriconazole |
|---|---|
| Also known as | tacrolimus, methylprednisolone sodium succinate, mycophenolate sodium |
| Sponsor | LI YAN |
| Drug class | Antifungal |
| Target | Enzyme |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action is not well understood, but it is thought to involve the inhibition of a key enzyme in the metabolic pathway of a specific disease-causing organism. This inhibition leads to a reduction in the growth and proliferation of the organism, ultimately resulting in the alleviation of symptoms.
Approved indications
- Treatment of invasive aspergillosis when used in combination with voriconazole
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
- A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
- Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia (PHASE2)
- Imetelstat Combinations in Relapsed AML (PHASE1)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant (PHASE1, PHASE2)
- Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combined with voriconazole CI brief — competitive landscape report
- Combined with voriconazole updates RSS · CI watch RSS
- LI YAN portfolio CI